Alopecia Totalis Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis
MALVERN, Pa., May 05, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 5, 2017 Category: Pharmaceuticals Source Type: clinical trials

Aclaris Therapeutics Submits Investigational New Drug Application for ATI-50001 to Treat Alopecia Universalis and Alopecia Totalis
MALVERN, Pa., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for its drug candidate... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 31, 2016 Category: Pharmaceuticals Source Type: clinical trials

Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
Conditions: Alopecia Areata; Alopecia Totalis; Alopecia UniversalisIntervention: Drug: Tofacitinib ointmentSponsor: Yale UniversityNot yet recruiting - verified June 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 21, 2016 Category: Research Source Type: clinical trials